EGFR Mutation Analysis Assay is based on PCR amplification and detection of target DNA using complementary primer pairs and oligonucleotide probes labeled with fluorescent dyes. This assay is designed to detect highly recurrent EGFR alterations in exon 18-21 (Exon 18 G719X; Exon 19 deletions; Exon 20 T790M, C797S, Exon20-Ins and S768I; Exon 21 L858R, L861Q); some less common EGFR mutations are not detectable in this test. For a full list of EGFR variants detectable in this assay, please contact NeoGenomics client services.
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein which can activate downstream RAS/RAF/MAPK pathway. Activating mutations in the EGFR gene have been identified in approximately 20% of non-small cell lung cancer (NSCLC). Most EGFR mutations occur in exons 18–21 and are predictive biomarkers for clinical response or resistance to certain EGFR tyrosine kinase inhibitors (TKIs). Identifying NSCLC patients with EGFR mutation is critical in determining patient eligibility for targeted TKI therapies.
- FFPE solid tumor tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Use cold pack for transporting block during summer to prevent block from melting. Slides can be packed at room temperature.
7 days